Bruker Corporation logo

Bruker Corporation

BRKR

NASDAQHealthcareMedical - Devices

Previous close

$59.56

−$0.36 · -0.60%

Aug 21, 4:00 PM ET

BRKR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

18

Overpriced

Momentum

61

Gaining

Sentiment

60

Mixed

Risk resilience

56

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Frank H. Laukien
Listed since
Aug 4, 2000
Employees
11,085

Market position

Day range

Current $59.56

52-week range

Current $59.56

Open
$59.60
Previous close
$59.92
Volume
3.2M
1.31× average
Average volume
2.44M
Average daily volume
Market cap
9.07B USD
Beta
1.28
Market reference 1
50-day average
$58.4742
+1.86% above average
200-day average
$47.1838
+26.23% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-85.21×
P/B (TTM)
3.78×
P/S (TTM)
2.59×
Dividend yield
0.34%

Profitability & efficiency

Gross margin
46.69%
Operating margin
3.61%
Net margin
-2.03%

Financial health

Debt / equity
0.8×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends57%36%15%-5%Gross margin, FY2021: 50.03%Gross margin, FY2022: 51.59%Gross margin, FY2023: 51.05%Gross margin, FY2024: 49.00%Gross margin, FY2025: 45.91%Operating margin, FY2021: 17.09%Operating margin, FY2022: 17.10%Operating margin, FY2023: 14.74%Operating margin, FY2024: 7.52%Operating margin, FY2025: 6.87%Net margin, FY2021: 11.46%Net margin, FY2022: 11.72%Net margin, FY2023: 14.41%Net margin, FY2024: 3.36%Net margin, FY2025: -0.25%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 50.03%. Gross margin FY2022 51.59%. Gross margin FY2023 51.05%. Gross margin FY2024 49.00%. Gross margin FY2025 45.91%. Operating margin FY2021 17.09%. Operating margin FY2022 17.10%. Operating margin FY2023 14.74%. Operating margin FY2024 7.52%. Operating margin FY2025 6.87%. Net margin FY2021 11.46%. Net margin FY2022 11.72%. Net margin FY2023 14.41%. Net margin FY2024 3.36%. Net margin FY2025 -0.25%.

Income trends

Revenue

3.44B USD+2.08%

Operating income

236M USD-6.76%

Net income

−8.6M USD−121.7M USD
Income trends across reported periods3.78B USD2.4B USD1.02B USD−353.11M USDRevenue, FY2021: 2.42B USDRevenue, FY2022: 2.53B USDRevenue, FY2023: 2.96B USDRevenue, FY2024: 3.37B USDRevenue, FY2025: 3.44B USDOperating income, FY2021: 413.3M USDOperating income, FY2022: 432.7M USDOperating income, FY2023: 436.9M USDOperating income, FY2024: 253.1M USDOperating income, FY2025: 236M USDNet income, FY2021: 277.1M USDNet income, FY2022: 296.6M USDNet income, FY2023: 427.2M USDNet income, FY2024: 113.1M USDNet income, FY2025: −8.6M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.42B USD. Revenue FY2022 2.53B USD. Revenue FY2023 2.96B USD. Revenue FY2024 3.37B USD. Revenue FY2025 3.44B USD. Operating income FY2021 413.3M USD. Operating income FY2022 432.7M USD. Operating income FY2023 436.9M USD. Operating income FY2024 253.1M USD. Operating income FY2025 236M USD. Net income FY2021 277.1M USD. Net income FY2022 296.6M USD. Net income FY2023 427.2M USD. Net income FY2024 113.1M USD. Net income FY2025 −8.6M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.44B USD3.37B USD2.96B USD2.53B USD2.42B USD
Cost of goods sold1.86B USD1.72B USD1.45B USD1.23B USD1.21B USD
Gross profit1.58B USD1.65B USD1.51B USD1.31B USD1.21B USD
Research and development395.2M USD376.5M USD294.8M USD235.9M USD220.8M USD
Selling, general, and administrative946.5M USD893.8M USD729.4M USD607.4M USD562.3M USD
Operating expenses1.34B USD1.4B USD1.08B USD873M USD796.3M USD
Interest income14.8M USD9.3M USD7.5M USD2.8M USD900K USD
Interest expense60.3M USD47.9M USD16.4M USD16.1M USD14.3M USD
Depreciation and amortization220.3M USD183.8M USD114.9M USD88.7M USD89.2M USD
Operating income236M USD253.1M USD436.9M USD432.7M USD413.3M USD
Net income−8.6M USD113.1M USD427.2M USD296.6M USD277.1M USD

Company facts updated Aug 24, 2026.

BRKR peers

ETFs holding BRKR

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research BRKR

research.disclaimer